Merrill keeps Neurocrine at neutral

Neurocrine Bioscience Inc. was maintained at neutral after the company reported results from a three-month phase 2 study for NBI-56418, its oral GnRH antagonist for endometriosis. While the highest dose, 150 mg, demonstrated a 5-pt reduction in Composite Pelvic Sign and Symptoms Score, a 3.7-point placebo effect was also apparent. Shares of the San Diego biotechnology company were down $1.24, or 2.12%, at $57.36 on volume of 880,608 shares versus the three-month running average of 652,759 shares. (Nasdaq: NBIX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.